📊 RNAC Key Takeaways
Is Cartesian Therapeutics, Inc. (RNAC) a Good Investment?
Cartesian Therapeutics exhibits acute financial distress with negative stockholders equity of -$126.2M and catastrophic operating losses of -$143.4M on minimal $2.8M revenue, indicating technical insolvency. While 599% YoY revenue growth signals early-stage product commercialization, the $73.9M annual operating cash burn rate will deplete the $125.1M cash position within 18-24 months absent capital restructuring or dramatic operational improvement, creating imminent solvency risk.
Revenue has spiked off a very small base, but the company remains deeply unprofitable with extreme negative operating and net margins, heavy cash burn, and a large accumulated deficit resulting in negative equity. While a strong current ratio and $125M in cash provide near‑term liquidity, the -$79M free cash flow and -$143M operating loss point to continued financing needs that strain fundamentals. Fundamentals warrant caution until operating leverage improves and the balance sheet is repaired.
Why Buy Cartesian Therapeutics, Inc. Stock? RNAC Key Strengths
- Exceptional 599% YoY revenue growth suggests early-stage product commercialization and market acceptance
- Adequate cash position of $125.1M provides near-term operational funding capacity
- Strong liquidity ratios (Current Ratio 8.65x, Quick Ratio 8.65x) provide working capital flexibility
- Strong liquidity: 8.65x current ratio and $125M cash
- Explosive YoY revenue growth (albeit from a small base)
- No reported long-term debt, reducing near-term interest burden
RNAC Stock Risks: Cartesian Therapeutics, Inc. Investment Risks
- Negative stockholders equity of -$126.2M represents technical insolvency on book value basis
- Unsustainable operating cash burn of -$73.9M annually with limited 18-24 month runway at current burn rates
- Operating losses of -$143.4M against $2.8M revenue demonstrate extreme unit economics with no visible path to profitability
- Liabilities of $422.7M exceed assets of $296.4M, creating substantial creditor and dilution risk
- Sustained heavy operating losses and extreme negative margins
- Negative stockholders' equity indicates balance-sheet risk and potential dilution
- Severely negative free cash flow with insufficient revenue scale
Key Metrics to Watch
- Monthly cash burn rate and remaining runway timeline
- Gross margin realization as revenue scales and manufacturing efficiency improves
- Achievement of clinical/regulatory milestones required for revenue growth acceleration
- Operating cash flow (quarterly)
- Cash & equivalents
Cartesian Therapeutics, Inc. (RNAC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 8.65x current ratio provides a solid financial cushion.
RNAC Profit Margin, ROE & Profitability Analysis
RNAC vs Healthcare Sector: How Cartesian Therapeutics, Inc. Compares
How Cartesian Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cartesian Therapeutics, Inc. Stock Overvalued? RNAC Valuation Analysis 2026
Based on fundamental analysis, Cartesian Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cartesian Therapeutics, Inc. Balance Sheet: RNAC Debt, Cash & Liquidity
RNAC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cartesian Therapeutics, Inc.'s revenue has declined by 55% over the 5-year period, indicating business contraction. The most recent EPS of $-4.49 indicates the company is currently unprofitable.
RNAC Revenue Growth, EPS Growth & YoY Performance
RNAC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | $13.8M | $-1.13 |
| Q2 2025 | N/A | -$1.8M | $-0.07 |
| Q1 2025 | $400.0K | -$17.7M | $-0.68 |
| Q3 2024 | N/A | -$9.0M | $-1.13 |
| Q2 2024 | $5.2M | -$11.4M | $0.54 |
| Q1 2024 | $5.8M | -$21.7M | $-4.24 |
| Q3 2023 | $6.6M | -$7.9M | $-0.05 |
| Q2 2023 | $5.2M | $8.6M | $0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cartesian Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
RNAC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cartesian Therapeutics, Inc. (CIK: 0001453687)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RNAC
What is the AI rating for RNAC?
Cartesian Therapeutics, Inc. (RNAC) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RNAC's key strengths?
Claude: Exceptional 599% YoY revenue growth suggests early-stage product commercialization and market acceptance. Adequate cash position of $125.1M provides near-term operational funding capacity. ChatGPT: Strong liquidity: 8.65x current ratio and $125M cash. Explosive YoY revenue growth (albeit from a small base).
What are the risks of investing in RNAC?
Claude: Negative stockholders equity of -$126.2M represents technical insolvency on book value basis. Unsustainable operating cash burn of -$73.9M annually with limited 18-24 month runway at current burn rates. ChatGPT: Sustained heavy operating losses and extreme negative margins. Negative stockholders' equity indicates balance-sheet risk and potential dilution.
What is RNAC's revenue and growth?
Cartesian Therapeutics, Inc. reported revenue of $2.8M.
Does RNAC pay dividends?
Cartesian Therapeutics, Inc. does not currently pay dividends.
Where can I find RNAC SEC filings?
Official SEC filings for Cartesian Therapeutics, Inc. (CIK: 0001453687) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RNAC's EPS?
Cartesian Therapeutics, Inc. has a diluted EPS of $-5.02.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RNAC a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cartesian Therapeutics, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RNAC stock overvalued or undervalued?
Valuation metrics for RNAC: ROE of N/A (sector avg: 15%), net margin of -4,658.6% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RNAC stock in 2026?
Our dual AI analysis gives Cartesian Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RNAC's free cash flow?
Cartesian Therapeutics, Inc.'s operating cash flow is $-73.9M, with capital expenditures of $5.5M. FCF margin is -2,838.6%.
How does RNAC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -4,658.6% (avg: 12%), ROE N/A (avg: 15%), current ratio 8.65 (avg: 2).